Chugai's HEMLIBRA® Receives the World's First Regulatory Approval from FDA for Hemophilia A with Inhibitors
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has approved the bispecific antibody emicizumab (US product name: HEMLIBRA®) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. This represents the first regulatory approval for HEMLIBRA® around the world. The US Biologics License Application (BLA) was submitted by Genentech, a member of Roche Group.
“We are pleased that HEMLIBRA, a biopharmaceutical created by Chugai scientists based on their exceptional idea, has received its first regulatory approval,” said Chugai’s President & COO, Tatsuro Kosaka. “HEMLIBRA is a first in class biopharmaceutical which is an advancement on the current limited treatment options available for patients with hemophilia A with inhibitors. We anticipate that patients will receive significant potential benefits from HEMLIBRA, which enables once-weekly subcutaneous injection as well as reduction of the bleeding risk.”
This regulatory approval is based on the data from two clinical studies, the results of HAVEN 1 study (NCT02622321) and the interim analysis of HAVEN 2 study (NCT02795767) in patients with hemophilia A with factor VIII inhibitors. HAVEN 1 included adult and adolescent patients and HAVEN 2 included pediatric patients, and were both conducted under a collaboration between Chugai, Roche and Genentech. In the HAVEN 1 study, adults and adolescents with hemophilia A with inhibitors who received HEMLIBRA prophylaxis (n=35) had a statistically significant and clinically meaningful 87% (95% CI: 72.3-94.3, p<0.0001) reduction in treated bleeds compared with those who received no prophylaxis (n=18). Interim results from the HAVEN 2 study, pediatric patients with hemophilia A with inhibitors showed that 87% of patients (95% CI: 66.4-97.2) who received HEMLIBRA prophylaxis (n=23) experienced zero treated bleeds. The most common adverse events (AEs) occurring in 10% or more of people treated with HEMLIBRA in pooled studies were injection site reactions, headache and joint pain (arthralgia).
HEMLIBRA was reviewed by the FDA under Priority Review. It was granted Breakthrough Therapy Designation by the FDA in adults and adolescents with hemophilia A with inhibitors in September 2015. Outside the US, emicizumab has been filed in the EU in June 2017 and data from HAVEN 1 and HAVEN 2 are being reviewed under Accelerated Assessment by the European Medicines Agency. In Japan, the drug received orphan drug designation by the Ministry of Health, Labour and Welfare for the prevention and reduction of bleeding episodes in patients with congenital FVIIl deficiency (hemophilia A) who developed inhibitors to FVIII in August 2016, and a new drug application was filed in July 2017.
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals, and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2016 of Chugai totaled 491.8 billion yen and the operating income was 80.6 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Clearhaus gir norske nettbutikker Apple Pay 21.6.2018 13:35 | Pressemelding
Apples mobilbetalingstjeneste, Apple Pay, har nettopp blitt lansert i Norge. Banker som Santander og Nordea er de første som introduserer tjenesten til norske forbrukere. Samtidig sørger den danske innløsningsvirksomheten Clearhaus for å gjøre den innovative, nye betalingsmetoden tilgjengelig i norske nettbutikker. Mobillommebok-teknologi som Apple Pay endrer hvordan folk kjøper og selger varer i butikker, i apper og på nettet. Apple Pay drives av Visa- og Mastercards tokeniseringsteknologi. Tjenesten gjør det mulig for iPhone-, Apple Watch-, iPad- og Mac-brukere å betale for varer på en enkel og sikker måte. Ved bruk av Apple Pay på nettet, trenger ikke forbrukere lenger å taste inn 16 kreditt- eller debetkortsiffer, utløpsdatoer og sikkerhetskoder. Etter å ha gjennomført et enkelt engangsoppsett med et kreditt- eller debetkort, kan brukere enkelt foreta kjøp i fysiske butikker eller i nettbutikker. Dette gjøres ved å plassere fingeren på touch id-platen eller ved å bruke ansiktsgjenk
Wipro Positioned as a Leader in Gartner’s Magic Quadrant 2018 for Oracle Application Services, Worldwide21.6.2018 13:22 | Pressemelding
Wipro Limited (NYSE: WIT) (BSE: 507685) (NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been positioned as a Leader in Gartner’s Magic Quadrant 2018 for Oracle Application Services, Worldwide. The report authored by Alan H Stanley, Susanne Matson, Jim Longwood and Allan Wilkins was published on February 28, 2018. This Magic Quadrant is focused on the full life-cycle of Oracle application services, spanning across project-based implementation and multi-year application management services (AMS). The report evaluated 19 service providers from across the globe and placed Wipro in the Leaders quadrant. Wipro is positioned the highest for its ‘ability to execute’ among all service providers. Please click here to view the complete Magic Quadrant report for Oracle Application Services 2018, Worldwide. Additionally, Wipro has been positioned in the Top 3 for three use cases namely, Implementation services, Man
Seoul Semiconductor Captures the Home Lighting Market with Its Innovative LED SunLike Technology21.6.2018 13:00 | Pressemelding
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a market leader in LED (light emitting diode) design and manufacturing, has launched into the global home lighting market with its innovative LED technology “SunLike.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005553/en/ Seoul Semiconductor, a market leader in LED design and manufacturing, launched into the global home lighting market with its innovative LED technology SunLike. SunLike implementing a spectrum similar to sunlight by lowering the blue light wavelength compared to an ordinary LED. (Graphic: Business Wire) Seoul Semiconductor announced that Mimi Lighting, a Korean LED lighting company, applied an innovative technology SunLike to the company’s home lighting products, which to be launched in the 3Q. SunLike applied to this home lighting is a natural light LED, which minimizes the disadvantages of artificial lighting and maximizes the advantages of natural l
MYbank Launches Star Plan to Support 1,000 Financial Institutions to Serve 30 Million SMEs in the Next Three Years21.6.2018 12:56 | Pressemelding
MYbank, a leading online private commercial bank in China with a focus on SME financing, today announced the launch of the Star Plan to open up its proven AI, computing and risk management capabilities to financial institutions in China. Through sharing these technological capabilities, MYbank aims to enable 1,000 financial institutions to provide more cost-effective financing services to 30 million SMEs and farmers in China in the next three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005666/en/ Announcing the launch of the Star Plan at the 2018 SME Financing Summit in Hangzhou, Eric Jing, Chairman of MYbank, Executive Chairman and CEO of Ant Financial, said, “The widespread application of advanced technologies in the SME financing space has dramatically improved risk management and lowered costs. With these innovations, we can unlock new opportunities for financial institutions and enable them to sustainabl
IFA 2018 : LG CEO and CTO to Outline Ambitious Strategy for ThinQ AI at IFA Opening Keynote21.6.2018 12:28 | Pressemelding
LG Electronics (LG) Chief Executive Officer Jo Seong-Jin and Chief Technology Officer Dr. I.P. Park will deliver a joint opening keynote at IFA 2018 to outline their vision for LG’s ThinQ strategy for Artificial Intelligence. The first IFA keynote for both executives, titled Think Wise, Be Free: Living Freer with AI will be delivered on Friday, August 31, in Hall 26b at Messe Berlin. With interest in all things AI at a peak, CEO Jo will provide his insight into how LG’s AI strategy will change customers’ lives based on its unique philosophy of an “open platform, open partnership and open connectivity”. Dr. Park will show how this technology comes to life in everyday products like refrigerators, TVs and washing machines, and how LG’s open AI strategy benefits consumers thanks to its focus of giving them both control and convenience. “The IFA Keynotes provide CEOs and top executives with a global media platform for forward thinking ideas and strategies,” said Jens Heithecker, Messe Berli
Servier and Taiho Announce Phase III Trial Data Demonstrates Significant Overall Survival Benefit of LONSURF® (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer21.6.2018 11:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced clinical data from the pivotal Phase III trial (TAGS) for LONSURF® (trifluridine and tipiracil, TAS-102) which showed significant improvement in overall survival (OS) for the treatment of patients with refractory metastatic gastric cancer (HR=0.69 [95% IC 0.56-0.85], p=0.0003). The median overall survival in patients treated with trifluridine/tipiracil and best supportive care (BSC) was 5.7 months as compared to 3.6 months when treated with placebo and BSC, and they had a 31% risk reduction of death. At 12-months, OS rates were 21.2% in the trifluridine/tipiracil group and 13.0% in the placebo group. In addition, the risk for disease progression measured by PFS, a key secondary endpoint, was reduced by 43% (HR: 0.57). The overall safety profile was consistent with the known safety profile of trifluridine/tipiracil in metastatic colorectal cancer (CRC), with mainly hematological adverse events reported. “The results presented to